Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H20ClNO.ClH |
Molecular Weight | 326.261 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCC(O)(C1=CC=CC=C1)C2=C(Cl)C=CC=C2
InChI
InChIKey=XYGSFNHCFFAJPO-UHFFFAOYSA-N
InChI=1S/C17H20ClNO.ClH/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18;/h3-11,20H,12-13H2,1-2H3;1H
DescriptionSources: https://www.drugbank.ca/drugs/DB04837Curator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15585 |
https://www.ncbi.nlm.nih.gov/pubmed/24671376
Sources: https://www.drugbank.ca/drugs/DB04837
Curator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15585 |
https://www.ncbi.nlm.nih.gov/pubmed/24671376
Chlophedianol (Clofedanol) is a centrally-acting cough suppressant, although the mechanism of action is not known. It is available in Canada under the trade name Ulone. It is not available in the United States. Chlophedianol (Clofedanol) suppresses the cough reflex by a direct effect on the cough center in the medulla of the brain. It also has local anesthetic and antihistamine properties, and may have anticholinergic effects at high doses.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mmx/ulone.html |
Primary | ULONE Approved UseIndicated for the symptomatic relief of nonproductive cough. Chlophedianol is used to provide relief of acute cough due to minor throat and bronchial irritation occurring with colds or inhaled irritants. |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 3 times / day steady, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: steady Dose: 20 mg, 3 times / day Sources: |
healthy, adult n = 12 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 12 Sources: |
Disc. AE: Allergic rash... AEs leading to discontinuation/dose reduction: Allergic rash (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Allergic rash | 1 patient Disc. AE |
20 mg 3 times / day steady, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: steady Dose: 20 mg, 3 times / day Sources: |
healthy, adult n = 12 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/604421/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/604421/ |
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/ulone.html
Usual adult and adolescent dose is 25 mg every six to eight hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6865909
The inhibition of specific binding of [3H]dextromethorphan (4 nM) to guinea pig brain homogenate was determined. Chlophedianol, a phenylalkylamine, had an IC value of 1300 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 341.14
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
||
|
CFR |
21 CFR 341.74
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
||
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
69QQ58998Y
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
1014329
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB01354MIG
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
100000085212
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
208-124-9
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
69QQ58998Y
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
511-13-7
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
C65312
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
m3336
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
C010432
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201313
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
DBSALT001414
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
DTXSID30965375
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY | |||
|
83813
Created by
admin on Fri Dec 15 16:25:56 GMT 2023 , Edited by admin on Fri Dec 15 16:25:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD